Overview

A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors

Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy, and safety of SHR-1901 in subjects with advanced malignant tumors.To explore the reasonable dosage of SHR-1901.
Phase:
Phase 1
Details
Lead Sponsor:
Suzhou Suncadia Biopharmaceuticals Co., Ltd.